

# CITATION REPORT

List of articles citing

**Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making**

**DOI: 10.1002/pds.4297**

**Pharmacoepidemiology and Drug Safety, 2017, 26, 1033-1039.**

**Source:** <https://exaly.com/paper-pdf/67031938/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
216	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <b>2017</b> , 20, 1009-1022		47
215	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 1018-1032	2.6	78
214	Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 1033-1039	2.6	158
213	Guidance to reinforce the credibility of health care database studies and ensure their appropriate impact. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 1013-1017	2.6	7
212	Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. <b>2018</b> , 10, 1758834018755072		9
211	The hope, hype and reality of Big Data for pharmacovigilance. <b>2018</b> , 9, 5-11		23
210	Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. <b>2018</b> , 26, 1172-1176		22
209	Real-World-Evidence-Forschung auf Basis von Big Data. <b>2018</b> , 24, 378-389		
208	. <b>2018</b> , 73, 1-12		2
207	Requests for post-registration studies (PRS), patients follow-up in actual practice: Changes in the role of databases. <b>2018</b> , 73, 13-24		5
206	Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 245-252	2.6	23
205	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 567-569	2.6	6
204	Task Force Report on the Validation of Diagnosis Codes and Other Outcome Definitions in the Japanese Receipt Data . <b>2018</b> , 23, 95-123		11
203	Real-world evidence research based on big data: Motivation-challenges-success factors. <b>2018</b> , 24, 91-98		25
202	Using machine learning to identify health outcomes from electronic health record data. <b>2018</b> , 5, 331-342		25
201	Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study. <b>2018</b> , 59, 1740-1752		54
200	Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. <b>2018</b> , 59, 1727-1739 <sup>41</sup>		

199	Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?. <b>2018</b> , 20, 2711-2723		16
198	Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. <b>2018</b> , 20, 60		25
197	Vancomycin Monotherapy May Be Insufficient to Treat Methicillin-resistant Staphylococcus aureus Coinfection in Children With Influenza-related Critical Illness. <b>2019</b> , 68, 365-372		21
196	Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. <b>2019</b> , 63, 18-26		17
195	The comparative effectiveness of fourth-line drugs in resistant hypertension: An application in electronic health record data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1267-1277	2.6	5
194	Building Trust in RWE Will Support Clearer Regulatory Uses. <b>2019</b> , 53, 417-419		
193	Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT). <b>2019</b> , 21, 415-422		4
192	Relative effectiveness and cost-effectiveness of the midwifery-led care in Nova Scotia, Canada: A retrospective, cohort study. <b>2019</b> , 77, 144-154		2
191	Net worth of networks: opportunities and potential. <b>2019</b> , 108, 1374-1376		0
190	The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data Task Force. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1640-1641	2.6	1
189	Identification of chemical changes in healthy breast tissue caused by chemotherapy using Raman and FTIR spectroscopy: A preliminary study. <b>2019</b> , 102, 102989		10
188	Compatibility of immunogenicity guidance by the EMA and the US FDA. <b>2019</b> , 11, 1619-1629		5
187	Machine learning methods for developing precision treatment rules with observational data. <b>2019</b> , 120, 103412		30
186	Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand?. <b>2019</b> , 71, 240-242		3
185	Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America. <b>2019</b> , 22, 739-749		20
184	A Structured Preapproval and Postapproval Comparative Study Design Framework to Generate Valid and Transparent Real-World Evidence for Regulatory Decisions. <b>2019</b> , 106, 103-115		16
183	The change in landscape after a new landmark is constructed: Radical hysterectomy for early cervical cancer and Minimally Invasive Surgery. <b>2019</b> , 153, 1-2		10
182	Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data. <b>2019</b> , 8, 285-299		4

181	Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews. <b>2019</b> , 22, 399-407	6
180	Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence. <b>2019</b> , 216847901983752	1
179	Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease. <b>2019</b> , 6, 90-99	1
178	Graphical Depiction of Longitudinal Study Designs in Health Care Databases. <b>2019</b> , 170, 398-406	58
177	The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers. <b>2019</b> , 9, e031434	7
176	Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review. <b>2019</b> , 9, e032522	
175	Preventive strategies and factors associated with surgically treated necrotising enterocolitis in extremely preterm infants: an international unit survey linked with retrospective cohort data analysis. <b>2019</b> , 9, e031086	7
174	The Role of Pharmacoepidemiology in Industry. <b>2019</b> , 98-125	1
173	Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study. <b>2019</b> , 38, 559-569	3
172	Single-agent ibrutinib in RESONATE-2 and RESONATE versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. <b>2019</b> , 98, 2749-2760	6
171	RWE Framework: An Interactive Visual Tool to Support a Real-World Evidence Study Design. <b>2019</b> , 6, 193-203	4
170	Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study. <b>2019</b> , 38, 559-569	17
169	Comparative and combined effectiveness of innovative therapies in cancer: a literature review. <b>2019</b> , 8, 205-216	1
168	Lessons from meta-analyses of randomized clinical trials for analysis of distributed networks of observational databases. <b>2019</b> , 18, 65-77	4
167	Real-World Epidemiologic Studies and Patient Registries. <b>2019</b> , 89-100	
166	The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics. <b>2020</b> , 14, 345-349	19
165	Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. <b>2020</b> , 107, 817-826	31
164	When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety. <b>2020</b> , 72, 4-6	5

163	Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 9-17	2.6	11
162	A Cost-Utility Analysis of Endovascular Thrombectomy in a Real-World Setting. <b>2020</b> , 47, 50-60		1
161	Critical c-Met-inhibitor interactions resolved from molecular dynamics simulations of different c-Met complexes. <b>2020</b> , 1203, 127456		14
160	Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. <b>2020</b> , 17, 993-1006		7
159	Using real-world evidence for pharmacovigilance and drug safety-related decision making by a resource-limited health authority: 10 years of experience in Taiwan. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1402-1413	2.6	1
158	Venous stenting for patients with outflow obstruction and leg ulcers: cost-effectiveness and budget impact analyses. <b>2020</b> , 9, 705-720		1
157	Real-world evidence: the devil is in the detail. <b>2020</b> , 63, 1694-1705		11
156	The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1532-1539	2.6	2
155	Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. <b>2020</b> , 25, 100445		8
154	Mandatory Registration and Results Reporting of Real-World Evidence Studies of FDA-Regulated Medical Products. <b>2020</b> , 95, 2609-2611		2
153	Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. <b>2020</b> , 10, e036102		8
152	Clearing heat and resolving phlegm for acute exacerbation of chronic obstructive pulmonary disease with the syndrome of phlegm-heat obstruction of the lung. <b>2020</b> , 48, 300060520945502		
151	Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. <b>2020</b> , 23, 1128-1136		27
150	Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. <b>2020</b> , 36, 474-480		9
149	Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1504-1513	2.6	3
148	Real-World Evidence: Pharmacoepidemiology for Daily Clinical Practice-An Experience from Colombia. <b>2020</b> , 7, 257-259		
147	Assessing the impact of unmeasured confounders for credible and reliable real-world evidence. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1219-1227	2.6	3
146	Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making. <b>2020</b> ,		7

145	Early triple-negative breast cancer in women aged 65: retrospective study of outcomes, resource use and costs, 2010-2016. <b>2021</b> , 17, 1039-1054		1
144	"Repurposing" Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years' Experience in One Medical Practice. <b>2020</b> , 9,		6
143	Methodologic approaches in studies using real-world data to measure pediatric safety and effectiveness of vaccines administered to pregnant women: a scoping review protocol. <b>2020</b> , 18, 2164-2170		1
142	Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review. <b>2020</b> , 23, 1497-1508		
141	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque Psoriasis treated with Biologics in a REAL world setting (PSO-BIO-REAL). <b>2020</b> , 34, 2566-2573		7
140	A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?. <b>2020</b> , 37, 3040-3058		19
139	Developing Markov Models From Real-World Data: A Case Study of Heart Failure Modeling Using Administrative Data. <b>2020</b> , 23, 743-750		1
138	Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: Experience from a national multicenter registry. <b>2020</b> , 61, 1109-1119		10
137	Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis. <b>2020</b> , 6, 1019-1027		45
136	Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. <b>2020</b> , 9, 603-614		24
135	Expanded Access as a source of real-world data: An overview of FDA and EMA approvals. <b>2020</b> , 86, 1819-1826	12	
134	Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs. <b>2020</b> , 61, 595-609		7
133	Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1228-1235	2.6	24
132	A Probiotic-Based Sanitation System for the Reduction of Healthcare Associated Infections and Antimicrobial Resistances: A Budget Impact Analysis. <b>2020</b> , 9,		4
131	Issues in the registration of database studies. <b>2020</b> , 121, 29-31		1
130	Economic Evaluations Informed Exclusively by Real World Data: A Systematic Review. <b>2020</b> , 17,		5
129	Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia. <b>2020</b> , 7, 2		2
128	Application of a Graphical Depiction of Longitudinal Study Designs to Managed Care Pharmacy Research. <b>2020</b> , 26, 268-274		4

127	Patient-Level Effectiveness Prediction Modeling for Glioblastoma Using Classification Trees. <b>2019</b> , 10, 1665	1
126	Vitamin and herbal supplements' use among patients with advanced gastrointestinal cancers included in eight clinical trials. <b>2020</b> , 146, 2089-2097	2
125	Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes. <b>2020</b> , 22 Suppl 3, 45-59	5
124	Using RWE research to extend clinical trials in diabetes: An example with implications for the future. <b>2020</b> , 22 Suppl 3, 35-44	7
123	Safety of Dienogest and Other Hormonal Treatments for Endometriosis in Real-World Clinical Practice (VIPOS): A Large Noninterventional Study. <b>2020</b> , 37, 2528-2537	6
122	Cost-effectiveness of superabsorbent wound dressing versus standard of care in patients with moderate-to-highly exuding leg ulcers. <b>2020</b> , 29, 235-246	1
121	The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness. <b>2021</b> , 109, 1189-1196	4
120	Temporal trends in childhood cancer survival in Egypt, 2007 to 2017: A large retrospective study of 14 808 children with cancer from the Children's Cancer Hospital Egypt. <b>2021</b> , 148, 1562-1574	1
119	Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases. <b>2021</b> , 148, 2203-2211	8
118	Benefits and limitations of real-world evidence: lessons from mutation-positive non-small-cell lung cancer. <b>2021</b> , 17, 965-977	10
117	The reporting of observational studies of drug effectiveness and safety: recommendations to extend existing guidelines. <b>2021</b> , 20, 1-8	1
116	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. <b>2021</b> , 143, 1002-1013	52
115	Patient-reported impact of Charcot-Marie-Tooth disease: protocol for a real-world digital lifestyle study. <b>2021</b> , 11, 21-33	0
114	Veridical Causal Inference using Propensity Score Methods for Comparative Effectiveness Research with Medical Claims. <b>2021</b> , 21, 206-228	0
113	Future ready real world data for healthcare optimisation and evidence-based decision making (Preprint).	
112	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. <b>2020</b> , 8, 612410	1
111	CuBlock: a cross-platform normalization method for gene-expression microarrays. <b>2021</b> ,	1
110	The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis. 1-14	8

109	Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments. <b>2021</b> , 42, 658-690		10
108	Real-world evidence to support regulatory decision making: New or expanded medical product indications. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 685-693	2.6	6
107	Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects. <b>2021</b> , 41, 303-319		8
106	Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment. 1-11		9
105	A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort. <b>2021</b> , 21, 432		3
104	Health Outcomes Research. 1-13		
103	Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice. <b>2021</b> , 48, 1552-1558		
102	Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients. <b>2021</b> , 39, 741-756		
101	Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA). <b>2021</b> , 11, e050682		2
100	When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?. <b>2021</b> ,		5
99	Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data. <b>2021</b> , 21, 95		0
98	Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan. <b>2021</b> , 8, 459-480		3
97	Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review. <b>2021</b> , 39, 3814-3824		1
96	Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance. <b>2021</b> , 10, 711-731		11
95	Old dog with new tricks: An introduction to real-world evidence for pharmacists. <b>2021</b> , 78, 2277-2280		1
94	A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. <b>2021</b> , 21, 924		3
93	Pragmatic Precision Psychiatry-A New Direction for Optimizing Treatment Selection. <b>2021</b> , 78, 1384-1390		9
92	Efficacy and tolerability of the hexanic extract of <i>Serenoa repens</i> compared to tamsulosin in moderate-severe LUTS-BPH patients. <b>2021</b> , 11, 19401		2



91	Comment on <b>Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment</b> 1-6	0
90	Individuals who develop drug-resistant epilepsy within a year after initial diagnosis have higher burden of mental and physical diseases one-year prior to epilepsy diagnosis as compared to those whose seizures were controlled during the same interval. <b>2021, 123, 108243</b>	0
89	Replication and reproducibility. <b>2021, 293-308</b>	
88	Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making. <b>2021, 27, 95-104</b>	0
87	La recherche clinique ^ partir d'entrep^s de donn^es. L'exp^rience de l'Assistance Publique ^ H^pitaux de Paris (AP^HP) ^ l'preuve de la pand^mie de Covid-19. <b>2020, 41, 303-307</b>	1
86	STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. <b>2021, 372, m4856</b>	24
85	Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?. <b>2018, 7, 111</b>	27
84	Real world evidence (RWE) ^ a disruptive innovation or the quiet evolution of medical evidence generation?. <b>2018, 7, 111</b>	49
83	Economic burden of inpatients infected with Klebsiella pneumoniae carbapenemase. <b>2019, 17, eGS4444</b>	3
82	Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes. <b>2018, 9, 252-257</b>	13
81	Demographic and Clinical Outcomes of Brazilian Patients With Stage III or IV Non-Small-Cell Lung Cancer: Real-World Evidence Study on the Basis of Deterministic Linkage Approach. <b>2021, 7, 1454-1461</b>	0
80	Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis. <b>2021, 12, 700012</b>	1
79	Use of real-world evidence in translational pharmacology research. <b>2021,</b>	0
78	PIKS: A Technique to Identify Actionable Trends for Policy-Makers Through Open Healthcare Data. <b>2021, 2, 1</b>	0
77	BIG DATA ANALYTICS IN PHARMACOVIGILANCE - A GLOBAL TREND. 19-24	
76	Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing. <b>2019, 2019,</b>	0
75	The power of health economics and outcomes research (HEOR) in making decisions that matter. <b>2021, 1, 23-32</b>	
74	The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework. <b>2021,</b>	0

73	Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment.. <b>2022</b> , 25, 443-450	0
72	Key Characteristics of Database Studies on Drug Effectiveness in the Postmarketing Stage: A Systematic Review. <b>2021</b> , 35, 327	
71	Real-world data: from planning to analysis. <b>2020</b> , 41, 9	2
70	CuBlock: A cross-platform normalization method for gene-expression microarrays.	
69	Core Concept: The pandemic is prompting widespread use-and misuse-of real-world data. <b>2020</b> , 117, 27754-27758	3
68	Post-Approval Regulatory Requirements. <b>2021</b> , 1-28	
67	Induced Native Phage Therapy for the Treatment of Lyme Disease and Relapsing Fever: A Retrospective Review of First 14 Months in One Clinic. <b>2021</b> , 13, e20014	
66	State of the Art: Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design. <b>2021</b> , 111, 77	1
65	Views from Academia, Industry, Regulatory Agencies, and the Legal System. <b>2021</b> , 73-111	
64	Reporting of abstracts in studies that used routinely collected data for exploring drug treatment effects: a cross-sectional survey.. <b>2022</b> , 22, 6	0
63	Promoting innovation while controlling cost: The UK's approach to health technology assessment.. <b>2022</b> ,	0
62	Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.. <b>2022</b> ,	13
61	Evaluating fitness-for-use of electronic health records in pragmatic clinical trials: reported practices and recommendations.. <b>2022</b> ,	0
60	Real World Data in Health Technology Assessment of Complex Health Technologies.. <b>2022</b> , 13, 837302	3
59	Cost analysis of negative-pressure wound therapy versus standard treatment of acute conflict-related extremity wounds within a randomized controlled trial.. <b>2022</b> , 17, 9	1
58	KEY LEARNINGS FROM ICER'S REAL WORLD EVIDENCE REASSESSMENT PILOT.. <b>2022</b> , 1-22	
57	Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.. <b>2022</b> , 13, 551	2
56	Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.. <b>2022</b> ,	1

55	DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).. <b>2022</b> , 14,	0
54	DataSheet_1.docx. <b>2020</b> ,	
53	Table_1.docx. <b>2021</b> ,	
52	Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study.. <b>2022</b> ,	0
51	Real World Evidence analysis of the FSH use in male idiopathic infertility. <b>2022</b> ,	0
50	Linking digital surveillance and in-depth virology to study clinical patterns of viral respiratory infections in vulnerable patient populations.. <b>2022</b> , 25, 104276	0
49	Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database.. <b>2022</b> , 1	
48	Shambhala-2: A Protocol for Uniformly Shaped Harmonization of Gene Expression Profiles of Various Formats. <b>2022</b> , 2,	1
47	Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations. 13,	2
46	Can Real-World Evidence Help Restore Decades of Health Inequalities by Informing Health Care Decision-Making? Certainly, and Here is How. 13,	
45	Rational and practical considerations to guide a target product profile for patient-centric drug product development with measurable patient outcomes [A proposed roadmap. <b>2022</b> , 177, 81-88	2
44	Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process. <b>2022</b> ,	0
43	The challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: expert panel recommendations. 1-9	
42	Cost analysis of the enhanced recovery after surgery protocol applied in advanced ovarian cancer: A secondary outcome of the PROFAST trial. <b>2022</b> ,	
41	The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Patient Disposition, Clinical Characteristics, and Treatment Persistence at 12 Months.	
40	A Review of Causal Inference for External Comparator Arm Studies.	0
39	Post-Approval Regulatory Requirements. <b>2022</b> , 699-725	
38	Real-world Medicare Healthcare Costs of Patients with Dupuytren's Contracture Treated with Collagenase or Fasciectomy. <b>2022</b> , 10, e4480	

37	Visualizations throughout pharmacoepidemiology study planning, implementation, and reporting.	
36	Safety and Effectiveness of a Catheter With Contact Force and 6-Hole Irrigation for Ablation of Persistent Atrial Fibrillation in Routine Clinical Practice. <b>2022</b> , 5, e2227134	0
35	Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis. <b>2022</b> , 52, 101590	1
34	Understanding variation in the results of real-world evidence studies that address the same question. <b>2022</b> ,	0
33	Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. <b>2022</b> , 175, 204-213	1
32	Reproducible Safety and Efficacy of Atezolizumab Plus Bevacizumab for HCC in Clinical Practice: Results of the AB-Real Study.	0
31	Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data. 033310242211230	4
30	A Review of Research Studies Using Data from the Administrative Claims Databases in Japan.	0
29	Trabectedin use in soft-tissue sarcoma patients in a real-world setting: data from an Italian national drug-access registry.	0
28	HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force. <b>2022</b> , 25, 1663-1672	2
27	Contemporary databases for real-world studies for three diverse healthcare systems in Asia: a scoping review for India, Thailand, and Taiwan (Preprint).	0
26	Which sperm parameter limits could really guide the clinical decision in assisted reproduction?.	0
25	Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: Systematic bias assessment of ovarian cancer treatment effectiveness. <b>2022</b> ,	0
24	Data challenges for externally controlled trials: a viewpoint (Preprint).	0
23	HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force.	0
22	Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry.	0
21	Comparative assessment of modern parameters of glycemic control in children with type 1 diabetes after switching to fast-acting insulin aspart using Flash Glucose Monitoring in real clinical practice. <b>2022</b> , 25, 458-467	0
20	Contemporary Databases in Real-world Studies Regarding the Diverse Health Care Systems of India, Thailand, and Taiwan: Protocol for a Scoping Review. <b>2022</b> , 11, e43741	0

- 19 Follicle-stimulating hormone effectiveness in male idiopathic infertility: What happens in daily practice?.
- 18 Sickle cell disease: a global patient registry review. **2022**, 2,
- 17 A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study. **2022**, 22,
- 16 Promoting reproducibility and integrity in observational research: one approach of an epidemiology research community. Publish Ahead of Print,
- 15 HARPER protocol template for real-world trials for evaluating treatment efficacy. **2023**, 2, 17-25
- 14 Quality assessment of real-world data. **2023**, 2, 10-16
- 13 Evidence on Real-World Data and Real-World Evidence As a Driver for Precision Medicine Implementation in Pharmacy Practice. **2023**, 1-12
- 12 Assessing Heterogeneity of Treatment Effect in Real-World Data. **2023**, 176, 536-544
- 11 The cost-effectiveness of targeted screening for congenital cytomegalovirus in newborns compared to clinical diagnosis in the US. **2023**, 166, 111450
- 10 Data Challenges for Externally Controlled Trials: Viewpoint. 25, e43484
- 9 Effect of the population health inpatient Medicare Advantage pharmacist intervention on hospital readmissions: A quasi-experimental controlled study. **2023**, 29, 266-275
- 8 Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making. **2023**, 26, 32-42
- 7 A systematic literature review of Real-World Evidence (RWE) on post-market assessment of medical devices.
- 6 Channeling of New Neuropsychiatric Drugs Impact on Safety and Effectiveness Studies. **2023**, 20, 375-388
- 5 Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA). **2023**, 9, e002802
- 4 Pragmatic considerations for negative control outcome studies to guide non-randomized comparative analyses: A narrative review.
- 3 Worldwide Trends in Registering Real-World Studies at ClinicalTrials.gov: A Cross-Sectional Analysis. Volume 16, 1123-1136
- 2 Perspectives on deprescribing in palliative care. 1-11

- 1 Data source profile reporting by studies that use routinely collected health data to explore the effects of drug treatment. **2023**, 23,

o